Drug use in Ireland and Northern Ireland: 2002/2003 drug prevalence survey: Health Board (Ireland) & Health and Social Services Board (Northern Ireland) results (Revised). by unknown
1National Advisory Committee on Drugs (NACD) & Drug and Alcohol Information and Research Unit (DAIRU) June 2005
This bulletin presents key findings at a local level from the first drug
prevalence survey of households to be carried out in both Ireland and
Northern Ireland. The survey sampled a representative number of people
aged between 15 and 64 during late 2002 and early 2003. The survey 
was undertaken by MORI MRC according to standards set by the European
Monitoring Centre for Drugs and Drug Addiction (EMCDDA). This bulletin
contains revised results (June 2005) relating to drug prevalence on a lifetime
(ever-used), last year (recent use), and last month (current use) basis for
illegal and other drugs including alcohol and tobacco for each Health Board (HB)
in Ireland and Health and Social Services Board (HSSB) in Northern Ireland.
Key Findings
■ Lifetime illegal drug prevalence
varied between 11% and 30%
across HB and HSSB areas.
■ There was almost a threefold
difference, ranging from 3% to
8%, across HB and HSSB areas in
the rates for recent illegal drug use.
■ Current illegal drug use rates
ranged between 0.2% and 5%
across areas.
■ Prevalence rates (lifetime, recent,
and current) tended to be higher
in the east of both Ireland and
Northern Ireland than elsewhere.
■ Cannabis was the main illegal 
drug used on a lifetime, recent,
and current basis in all HB and
HSSB areas.
■ Prevalence rates for other illegal
drugs were considerably lower
than for cannabis across all areas
and for all periods (lifetime, 
recent, and current use).
■ In the HSSB areas, ecstasy was 
the most commonly reported
illegal drug used in the last year,
after cannabis.
■ In HB areas, cocaine and ecstasy
were the most commonly reported
illegal drugs used in the last year,
after cannabis.
■ The profile of illegal drug users
was similar between areas –
generally prevalence rates were
higher amongst men and young
people.
■ Prevalence rates for sedatives,
tranquillisers and anti-depressants
were higher amongst older people
and women in most areas.
■ Current alcohol prevalence rates
varied between 64% and 81%
across HB and HSSB areas. Rates
of current use were higher among
males than females. In general,
younger adults reported higher
rates of current use.
■ Current tobacco prevalence rates
ranged from 29% to 41% in HB
and HSSB areas. Rates of lifetime
and current use were generally
higher among males than females
although in a number of areas this
position was reversed. Younger
adults in all areas reported higher
rates of current use.
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Introduction
The survey was commissioned by the National Advisory
Committee on Drugs (NACD) in Ireland and the Drug and
Alcohol Information and Research Unit (DAIRU) within the
Department of Health, Social Services and Public Safety
(DHSSPS) in Northern Ireland.
The main focus of the survey was to obtain prevalence rates 
for key illegal drugs such as cannabis, ecstasy, cocaine, heroin,
etc. on a lifetime (ever used), last year (recent use), and last
month (current use) basis. Similar prevalence questions 
were also asked of alcohol, tobacco, and other drugs (e.g.
tranquillisers); attitudinal and demographic information 
was also sought from respondents.
Following open tender, the contract for conducting the 
survey was awarded to MORI MRC.
Methodology
The questionnaire and methodology for this survey were 
based on best practice guidelines drawn up by the EMCDDA. 
The questionnaires were administered through face-to-face
interviews with respondents aged between 15-64 normally
resident in households in Ireland and Northern Ireland. Thus
persons outside these age ranges, or who do not normally 
reside in private households, have not been included in the
survey. This approach is commonly used throughout the EU 
and because of the exclusion of those living in institutions 
(for example, prisons, nursing homes) this type of prevalence
survey is usually known as a general population survey.
Fieldwork for the survey was carried out between October 
2002 and April 2003 and the final achieved sample was 
8,434 (4,918 in Ireland and 3,516 in Northern Ireland). 
The response rate for the survey was 70% in Ireland and 63% 
in Northern Ireland. The sample was weighted by gender, age,
Health Board in Ireland and Health and Social Services Board
area in Northern Ireland, to maximise its representativeness 
of the general population.
Details of the methodology have been summarised in a paper
published on the websites of the NACD (http://www.nacd.ie/)
and the DHSSPS (http://www.dhsspsni.gov.uk/) and a
comprehensive technical report containing copies of the
questionnaires used in both jurisdictions will be published
separately.
Please Note
■ Prevalence rates for “any illegal drugs” refers to the 
reported use of one or more of the following: amphetamines,
cannabis, cocaine powder, crack, ecstasy, heroin, LSD, magic
mushrooms, poppers or solvents – see table footnotes.
■ Questions relating to anabolic steroids and Nubain® were
asked only in Northern Ireland. To maintain comparability 
of overall illegal drug prevalence rates between Ireland 
and Northern Ireland, these drugs are not included in the
calculation of the prevalence rates for “any illegal drugs”.
The drugs included under “other opiates” differed between
Ireland and Northern Ireland – for full details see the footnotes 
to the tables. Consequently, it is not appropriate to compare 
the prevalence of “other opiates” between the two jurisdictions.
What is Prevalence?
The term prevalence refers to the proportion 
of a population who have used a drug over a
particular time period. In general population
surveys, prevalence is measured by asking
respondents in a representative sample drawn
from the population to recall their use of drugs.
The three most widely used recall periods are:
lifetime (ever used a drug), last year (used a drug
in the last twelve months), and last month (used 
a drug in the last 30 days). Provided a sample is
representative of the total population, prevalence
information obtained from a sample can be used
to infer prevalence in the population.
Lifetime prevalence refers to the proportion of the
sample that reported ever having used the named
drug at the time they were surveyed. A person who
records lifetime prevalence may – or may not – 
be currently using the drug. Lifetime prevalence
should not be interpreted as meaning that people
have necessarily used a drug over a long period 
of time or that they will use the drug in the future.
Last year prevalence refers to the proportion of
the sample that reported using a named drug in
the year prior to the survey. For this reason, last
year prevalence is often referred to as recent use.
Last month prevalence refers to the proportion 
of the sample that reported using a named drug 
in the 30 day period prior to the survey. Last month
prevalence is often referred to as current use. 
A proportion of those reporting current use may 
be occasional (or first-time) users who happen to
have used in the period leading up to the survey –
it should therefore be appreciated that current use
is not synonymous with regular use.
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Understanding the Results 
in this Bulletin
Initial results from the Drug Prevalence Survey were published 
in Bulletin 1 (October 2003, revised June 2005), which gave
lifetime, last year, and last month prevalence rates for key 
drugs for the Island of Ireland, Ireland, and Northern Ireland. 
This bulletin contains comparable information for Ireland and 
its constituent Health Boards and Northern Ireland and its
constituent Health and Social Services Boards. Prevalence rates
for alcohol and tobacco (and, relating to Northern Ireland only,
for anabolic steroids and Nubain®) have also been included in
the tables. Results are given for all respondents from each area,
and are also presented by gender and by age (younger adults
aged 15-34 and older adults aged 35-64).
Readers should note that the total sample size for each group 
is given at the head of each column. As in all sample surveys, 
the greater the sample size the more statistically reliable are 
the results. Some of the differences in prevalence rates in the
tables will be attributable to natural sample variations. Detailed
confidence intervals for all of the figures contained in this bulletin
will be posted on the websites of the NACD and DHSSPS in 
due course.
Where no reported use is stated this indicates that no
respondent in the survey reported use of a particular drug. 
It does not mean that there was no use of that drug in the 
area, although it is indicative of low levels of use.
A brief description of the key results in the four Health and 
Social Services Board areas in Northern Ireland (see Map 1, page
4) and in the ten Health Board areas in Ireland (see Map 2, page
7) are given below. The following overall patterns were noted:
■ There was considerable variation in prevalence rates 
between areas over lifetime, last year, and last month
periods. In general, prevalence rates varied more by area 
in Ireland than in Northern Ireland and tended to be highest
in eastern areas of both Ireland and Northern Ireland. It is not
possible to definitively attribute factors associated with these
variations at this stage. However, findings from other drug
prevalence surveys suggest drug use tends to be higher in
more urbanised areas than in rural areas. These differences
will be explored in a later bulletin.
■ The highest lifetime rate of illegal drug use recorded across
both jurisdictions was 30% and the lowest was 11%. Recent
illegal drug use ranged between 3% and 8% and current use
between 0.2% and 5%. This means that estimates of current
drug use range from 1 person in 500 (0.2%) currently using
illegal drugs in one area and up to 1 person in 20 (5%)
currently using illegal drugs in another area.
■ In all areas, cannabis was by far the main illegal drug used 
on a lifetime, recent, and current basis with at least twice 
the prevalence rate of the next most commonly used illegal
drug. In relation to current use, cannabis prevalence rates in
all areas were at least three times higher than the prevalence
rate for the next most commonly used illegal drug. Lifetime
cannabis prevalence rates across areas varied from 9% to
27%; recent use from 2% to 8%; and current use from
0.2% to 5%.
■ All other illegal drugs had lower prevalence rates than
cannabis. For example, the highest prevalence rate for 
recent use of ecstasy and cocaine was 2% compared to 
8% for cannabis. In most areas there were no reports of
heroin and crack use by those surveyed. This does not mean
that there was no heroin or crack use in these areas although
it is indicative of low levels of use.
■ Although drug use varied considerably between different
areas, the profile of illegal drug users showed a great deal 
of consistency – prevalence rates for lifetime, recent and
current use were higher amongst men than women and
higher amongst young people than older people.
■ Prevalence rates for other drugs such as sedatives,
tranquillisers and anti-depressants, were higher amongst 
older people and women in most areas. Lifetime use of
sedatives, tranquillisers and anti-depressants ranged from 
6% to 23% (although most areas had prevalence rates in
excess of 10%); recent use varied between 2% and 14%;
and current use between 2% and 10%.
■ Current alcohol prevalence rates varied between 64% 
and 81% across HB and HSSB areas. Rates of current use
were higher among males than females. In general, younger
adults reported higher rates of current use, however, in a
small number of HB and HSSB areas older adults reported
higher rates.
■ Current tobacco prevalence rates ranged from 29% to 41%
in HB and HSSB areas. Rates of lifetime and current use 
were generally higher among males than females although 
in a number of areas this position was reversed. While older
adults generally had higher lifetime prevalence rates, younger
adults in all areas reported higher rates of current use.
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Northern Ireland – 
Results by Health and 
Social Services Board
Prevalence rates for Northern Ireland are given in Table 1.
Map 1: Northern Ireland – 
Health and Social Services Board Areas
Eastern Health and Social Services Board 
(EHSSB)
(see Table 2)
Any illegal drugs
Over one fifth (22%) of respondents reported ever having 
taken an illegal drug, 7% had done so in the previous year 
and 4% in the previous month. Each of these rates was higher
than the corresponding Northern Ireland figure. Males were more
likely to report current use of illegal drugs (7%) than females
(1%) and young adults aged 15-34 had higher current usage
rates (7%) than their older counterparts (1%).
Cannabis
Cannabis was the most commonly used illegal drug, with nearly
one fifth (19%) of respondents reporting ever having taken it. 
Six per cent had taken it in the previous year and 3% in the
previous month.
Other illegal drugs
Apart from cannabis, the highest levels of lifetime use were
recorded for ecstasy (7%); poppers (6%); amphetamines and
LSD (each 5%); magic mushrooms (4%); and solvents and
cocaine (each 2%). The lifetime prevalence of all other illegal
drugs was less than 1% – anabolic steroids (0.8%); and heroin
and crack (each 0.1%).
In the past year, ecstasy (2%) and amphetamines (1%) were
the main drugs reported other than cannabis. In the month prior
to the survey, ecstasy (0.5%) was the most frequently reported
illegal drug used apart from cannabis.
Sedatives, tranquillisers and anti-depressants
Twenty two per cent of respondents reported ever using
sedatives, tranquillisers and anti-depressants, 13% had done so
in the previous year and 10% in the previous month. Rates were
higher amongst female respondents (13% used in the previous
month) than males (7%). Older adults reported a higher last
month prevalence rate (13%) than younger adults (6%).
Alcohol
Ninety one per cent of the respondents in the EHSSB area
reported that they had ever taken an alcoholic drink, 82% had
done so in the previous year and 72% in the previous month.
Males (79%) were more likely to report current drinking than
females (66%), and both these rates were slightly in excess 
of the corresponding Northern Ireland figures. Young adults and
older adults had similar current drinking prevalence rates (72%).
Tobacco
Fifty nine per cent of respondents reported ever smoking
tobacco, 40% had done so in the previous year and 37% 
in the previous month. Although male respondents were 
more likely to report ever having smoked than females, current
prevalence rates for female respondents (38%) were slightly
higher than for male respondents (36%). Young adults were 
also slightly more likely to report current smoking than their 
older counterparts.
Northern
Southern
Western
Eastern
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Northern Health and Social Services Board 
(NHSSB)
(see Table 3)
Any illegal drugs
Nearly one fifth (18%) of respondents reported ever having
taken an illegal drug, 6% had done so in the previous year 
and 4% in the previous month. Lifetime prevalence was lower
than the corresponding Northern Ireland figure, and last month
prevalence slightly higher. Males were more likely to report
current use of illegal drugs (7%) than were females (1%) and
young adults aged 15-34 reported higher current usage rates
(7%) than their older counterparts (1%).
Cannabis
Cannabis was the most commonly used illegal drug, with around
one in seven (14%) of respondents reporting ever having taken
it. Five per cent had taken it in the previous year and 3% in the
previous month.
Other illegal drugs
Other than cannabis, the highest levels of lifetime use were
recorded for poppers (7%); ecstasy (6%); magic mushrooms
and LSD (each 5%); amphetamines (4%); and solvents (3%).
The lifetime prevalence of all other illegal drugs was 1% or lower
– cocaine (1%); crack (0.3%); heroin (0.4%); anabolic steroids
(0.2%); and Nubain® (0.1%).
In the year prior to the survey, ecstasy (2%) was the main 
drug reported other than cannabis – no other drug had a last
year prevalence rate exceeding 1%. In the month prior to the
survey, ecstasy (1%) was again the most frequently reported
illegal drug used apart from cannabis: there was little or no
reported use by respondents of illegal drugs other than 
cannabis or ecstasy.
Sedatives, tranquillisers and anti-depressants
Twenty three per cent of respondents reported ever using
sedatives, tranquillisers and anti-depressants, 14% had done so
in the previous year and 10% in the previous month. Rates were
higher amongst female respondents (14% used in the previous
month) than males (7%). Older adults had higher last month
prevalence (14%) than younger adults (6%).
Alcohol
Eighty six per cent of the respondents in the NHSSB area
reported that they had ever taken an alcoholic drink, 77% had
done so in the previous year and 65% in the previous month.
Although males (68%) were more likely to report current
drinking than females (61%), male current drinking prevalence
was lower than for males in Northern Ireland as a whole (73%).
Current drinking prevalence was slightly higher for younger adults
(65%) than for older adults (64%).
Tobacco
Fifty five per cent of respondents reported ever smoking tobacco,
38% had done so in the previous year and 35% in the previous
month. Male respondents were more likely to report ever having
smoked than females, and were also slightly more likely to report
current smoking (36%) than females (35%). More young adults
reported current smoking than their older counterparts.
Southern Health and Social Services Board 
(SHSSB)
(see Table 4)
Any illegal drugs
Nearly one fifth (19%) of respondents reported ever having
taken an illegal drug, 5% had done so in the previous year and
2% in the previous month. These rates are slightly lower than 
the corresponding Northern Ireland prevalence rates. Males 
were more likely to report current use of illegal drugs (3%) 
than females (1%) and young adults aged 15-34 had higher
current usage rates (4%) than their older counterparts (0.5%).
Cannabis
Cannabis was the most commonly used illegal drug, with around
one in six (16%) of respondents reporting ever having taken it.
Four per cent had taken it in the previous year and 2% in the
previous month.
Other illegal drugs
Other than cannabis, the highest levels of lifetime use were
recorded for LSD, solvents, ecstasy, poppers, and magic
mushrooms (each 3%); amphetamines (2%); cocaine (1%);
and anabolic steroids (0.4%). No respondents reported taking
crack, heroin, or Nubain®.
In the year prior to the survey, no illegal drug other than cannabis
had a prevalence rate exceeding 1%.
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Sedatives, tranquillisers and anti-depressants
Twenty one per cent of respondents reported ever using
sedatives, tranquillisers and anti-depressants, 11% had done 
so in the previous year and 9% in the previous month. Rates
were higher amongst female respondents (11% used in the
previous month) than males (7%). Older adults (13%) showed
higher current prevalence rates than younger adults (3%) – 
the current prevalence rate amongst young adults is lower 
than the corresponding Northern Ireland figure of 5%.
Alcohol
Eighty six per cent of the respondents in the SHSSB area
reported that they had ever taken an alcoholic drink, 76% 
had done so in the previous year and 64% in the previous
month. Males (70%) were more likely to report current drinking
than females (59%), and both these rates were slightly lower
than the corresponding Northern Ireland figures. Young adults
(72%) reported considerably higher current drinking than older
adults (59%).
Tobacco
Fifty seven per cent of respondents reported ever smoking
tobacco, 39% had done so in the previous year and 35% 
in the previous month. Male respondents were more likely 
to report ever having smoked than females, and the current
prevalence rate for males (37%) was slightly higher than 
for females (33%).
Western Health and Social Services Board 
(WHSSB)
(see Table 5)
Any illegal drugs
Nearly one fifth (19%) of respondents reported ever having
taken an illegal drug, 6% had done so in the previous year and
3% in the previous month. Lifetime, last year and last month
prevalence rates were slightly lower than the corresponding
Northern Ireland figures. Males were more likely to report current
use of illegal drugs (5%) than females (1%) and young adults
aged 15-34 had higher current usage rates (5%) than their older
counterparts (1%).
Cannabis
Cannabis was the most commonly used illegal drug, with around
one in six (16%) of respondents reporting ever having taken it.
Five per cent had taken it in the previous year and 3% in the
previous month.
Other illegal drugs
Other than cannabis, the highest levels of lifetime use were
recorded for ecstasy and magic mushrooms (each 5%); poppers,
LSD, amphetamines, and solvents (each 4%); anabolic steroids
(2%); and cocaine (2%). The lifetime prevalence of all other
illegal drugs was lower than 1% – crack (0.9%); heroin (0.4%);
and Nubain® (0.2%).
In the year prior to the survey, ecstasy (1%) was the main 
drug reported other than cannabis – no other drug had a last
year prevalence rate exceeding 1%. In the month prior to the
survey, no drug other than cannabis was used by more than 
1% of respondents.
Sedatives, tranquillisers and anti-depressants
Twenty per cent of respondents reported ever using sedatives,
tranquillisers and anti-depressants, 11% had done so in the
previous year and 9% in the previous month. Rates were higher
amongst female respondents (12% used in the previous month)
than males (6%). Older adults showed higher current prevalence
rates than younger adults.
Alcohol
Eighty seven per cent of the respondents in the WHSSB area
reported that they had ever taken an alcoholic drink, 78% had
done so in the previous year and 65% in the previous month.
Males (69%) were more likely to report current drinking than
females (61%): figures for both males and females are slightly
lower than the corresponding figures for Northern Ireland. Young
adults (73%) reported considerably higher current drinking than
older adults (59%).
Tobacco
Sixty three per cent of respondents reported ever smoking
tobacco, 45% had done so in the previous year and 41% 
in the previous month. Male respondents were more likely to 
report ever having smoked than females, but females (41%)
showed a slightly higher current prevalence rate than males
(40%). Young adults were more likely to report current smoking
(43%) than their older counterparts (39%).
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Ireland – Results 
by Health Board
Prevalence rates for Ireland are given in Table 6.
Map 2: Ireland – Health Board Areas
* ERHA – Eastern Regional Health Authority incorporating:
East Coast Area Health Board (ECAHB)
Northern Area Health Board (NAHB)
South Western Area Health Board (SWAHB)
East Coast Area Health Board (ECAHB)
(see Table 7)
Any illegal drugs
Just over a quarter (26%) of respondents reported they had 
ever taken an illegal drug, 6% had done so in the previous year
and 4% in the previous month. Each of these rates was higher
than the corresponding national figure.
Males reported lifetime prevalence rates nearly double that of
females (34% compared to 18%). This gender difference was
more pronounced in the rates for recent and current use with
men reporting rates up to four times as high as those reported
by women.
Lifetime prevalence rates among young adults (36%) were twice
that of older adults (18%). The age differential was higher again
for rates for recent and current use with the younger age group
reporting rates up to eight times higher than that of older adults.
Cannabis
Cannabis was the most commonly used illegal drug, almost a
quarter (24%) of respondents reported ever taking the drug, 6%
had done so in the previous year and 4% in the previous month.
Rates of cannabis use were consistently higher among males and
the younger 15-34 age group.
Other illegal drugs
Apart from cannabis, the highest levels of lifetime use reported
were for cocaine powder and magic mushrooms (each 6%);
ecstasy, amphetamines and LSD (each 5%); poppers (4%); 
and solvents (2%).
In the past year, ecstasy and cocaine powder (2%) were the
main other drugs reported. In the month prior to the survey,
ecstasy was the most frequently reported drug used (1%) 
other than cannabis.
Minimal levels of crack (1%) and heroin (0.7%) use were
reported by those surveyed.
Sedatives, tranquillisers and anti-depressants
Fourteen per cent of respondents reported ever using sedatives,
tranquillisers and anti-depressants, 7% had done so in the
previous year and 5% in the previous month. These rates were
substantially higher among females and older adults. However,
age and gender differences were less pronounced in the rates 
for current and recent use.
Alcohol
Ninety four per cent of respondents reported that they had ever
taken an alcoholic drink, 89% had done so in the previous year
and 81% in the previous month. All alcohol prevalence rates
were higher than the corresponding national rates.
In general, prevalence rates were higher among males and 
young adults. However, a slightly higher proportion of older 
adults (82%) than younger adults (80%) reported current 
use of alcohol; this pattern was at variance with most other
health boards.
Tobacco
Sixty two per cent of respondents reported ever smoking
tobacco, 39% had done so in the previous year and 32% in 
the previous month. While lifetime prevalence rates were higher
among females, recent and current rates were higher among
males. Both lifetime and recent prevalence rates were higher
than the corresponding national rates.
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Midland Health Board (MHB)
(see Table 8)
Illegal drug use
Eleven per cent of respondents reported that they had ever 
taken an illegal drug, 3% had done so in the previous year 
and 1% in the previous month. Illegal drug use in this health
board area primarily related to the use of cannabis for which
similar rates were reported.
Apart from cannabis, the drugs with the highest lifetime rates
were LSD, magic mushrooms, ecstasy and poppers (each 2%);
cocaine powder and solvents (each 1%).
Males and young adults reported higher prevalence rates.
All prevalence rates were lower than the corresponding 
national rates.
Sedatives, tranquillisers and anti-depressants
Ten per cent of respondents reported ever using sedatives,
tranquillisers and anti-depressants, 4% had done so in the previous
year and 3% in the previous month. Prevalence rates were higher
among females and older adults, with one exception – the current
prevalence rate was the same for males and females (3%).
Alcohol
Eighty seven per cent of respondents reported that they had 
ever taken an alcoholic drink, 79% had done so in the previous
year and 69% in the previous month. Younger adults and 
males reported higher prevalence rates although the lifetime
prevalence rate among male respondents was similar to the
corresponding national rate.
Tobacco
Sixty per cent of respondents reported ever smoking tobacco,
37% had done so in the previous year and 31% in the previous
month. The lifetime rate for tobacco use was higher than the
corresponding national rate, as was the rate for recent and
current use among young adults. In contrast to the national
pattern, a slightly higher proportion of women (32%) than 
men (31%) reported current tobacco use.
Mid-Western Health Board (MWHB)
(see Table 9)
Illegal drug use
Twelve per cent of respondents reported they had ever taken 
an illegal drug, 3% had done so in the previous year and 2% 
in the previous month. Illegal drug use in this health board area
primarily related to the use of cannabis for which similar rates
were reported.
Prevalence rates were higher among young adults and among
males than females although the gender difference was less
marked in the rates for current and recent use.
Apart from cannabis, highest lifetime levels of use were recorded 
for ecstasy and magic mushrooms (each 2%); amphetamines,
cocaine powder, LSD, solvents and poppers (each 1%). No use 
of heroin or crack was reported by respondents.
In the past year, rates of 1% each were reported for cocaine
powder and ecstasy. In the month prior to the survey no use of an
illegal drug, other than cannabis, was reported by those surveyed.
Sedatives, tranquillisers and anti-depressants
Twelve per cent of respondents reported ever using sedatives,
tranquillisers and anti-depressants, 4% had done so in the
previous year and 3% in the previous month.
The lifetime rate of use among older adults was higher than 
the corresponding national rate. Prevalence rates among males
for lifetime and recent use was higher than that of females. 
For current use, the prevalence rate was the same.
Alcohol
Eighty eight per cent of respondents reported that they had ever
taken an alcoholic drink, 81% had done so in the previous year
and 72% in the previous month. Prevalence rates were higher
among males than females and among younger adults. Alcohol
prevalence rates in the health board area were lower than the
national rates.
Tobacco
Fifty nine per cent of respondents reported ever smoking
tobacco, 36% had done so in the previous year and 30% in 
the previous month. In general, prevalence rates were higher
among younger adults and males. However, the prevalence 
rate for tobacco use in the year prior to the survey was higher
among females (36%) than males (35%), a pattern which 
was at variance to that reported at national level.
North Eastern Health Board (NEHB)
(see Table 10)
Illegal drug use
Nineteen per cent of respondents reported they had ever taken
an illegal drug, 6% had done so in the previous year and 2% 
in the previous month. Males reported lifetime prevalence rates
almost double (25%) that of females (13%). Nearly one third
(32%) of young adults had ever used an illegal drug, this rate
was substantially higher than the corresponding national figure
(26%). In contrast, 7% of older adults had ever used an illegal
drug, a rate which was substantially lower than the corresponding
national figure (12%). The difference in the rates between the
two age groups was consistently large for lifetime, recent and
current use.
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Cannabis accounted for almost all illegal drug use – 18% had
ever taken cannabis, 5% had done so in the previous year and
2% in the previous month.
Apart from cannabis, highest lifetime levels of use were recorded
for poppers (5%); magic mushrooms, solvents, amphetamines
and ecstasy (each 3%); LSD (2%); and cocaine powder (1%).
Higher than average rates of use were reported for solvents
(7%) and poppers (9%), particularly among young adults. 
In contrast, lower than average rates were recorded for lifetime
use of cocaine powder (1%).
Sedatives, tranquillisers and anti-depressants
Six per cent of respondents reported ever using sedatives,
tranquillisers and anti-depressants, 2% had done so in the
previous year and 2% in the previous month. These rates 
were substantially lower than the corresponding national 
rates. For example, lifetime rates among both younger and 
older adults were less than half that of the national rates.
Alcohol
Eighty eight per cent of those surveyed reported that they 
had ever taken an alcoholic drink, 82% had done so in 
the previous year and 71% in the previous month. Alcohol
prevalence rates across age and gender were somewhat 
lower than the corresponding national rates.
Tobacco
Fifty eight per cent of respondents reported ever smoking
tobacco, 35% had done so in the previous year and 31% in 
the previous month. Lifetime prevalence rates were somewhat
lower than the national rates, in particular the recent (32%) and
current (28%) rates among females.
North Western Health Board (NWHB)
(see Table 11)
Illegal drug use
Eleven per cent of respondents reported ever taking an illegal
drug, 3% had done so in the previous year and 0.2% in the
previous month. These rates were substantially lower than the
corresponding national rates, with lifetime use among young
adults (13%) half that of the national rate (26%).
Cannabis accounted for almost all illegal drug use. Nine per 
cent reported ever taking cannabis, 2% had done so in the
previous year and 0.2% in the previous month. Lifetime, 
last year and last month prevalence rates were lower than 
the corresponding national rates.
Apart from cannabis, highest levels of lifetime use were recorded
for magic mushrooms (2%); poppers and solvents (each 1%).
No heroin, cocaine or crack use was reported by those surveyed.
Magic mushrooms were the only drug, aside from cannabis,
whose use was reported in the past year. Cannabis was the 
only drug currently used by those surveyed.
Sedatives, tranquillisers and anti-depressants
Eleven per cent of respondents reported ever using sedatives,
tranquillisers and anti-depressants, 6% had done so in the
previous year and 5% in the previous month. Patterns of use
largely followed the national picture with higher rates among
females than males and among older than younger adults. Overall,
lifetime prevalence rates were slightly lower than the national
rates whereas recent and current rates were somewhat higher.
Alcohol
Eighty six per cent of those surveyed reported that they had 
ever taken an alcoholic drink, 77% had done so in the previous
year and 68% in the previous month. Prevalence rates were
lower than the corresponding national rates, particularly among
the women surveyed.
Tobacco
Fifty eight per cent of respondents reported ever smoking tobacco,
33% had done so in the previous year and 29% in the previous
month. Prevalence rates were lower than the corresponding
national rates, in particular among females and young adults.
Northern Area Health Board (NAHB)
(see Table 12)
Any illegal drug
Thirty per cent of respondents reported they had ever taken 
an illegal drug, 8% had done so in the previous year and 5% 
in the previous month. All prevalence rates were higher than 
the corresponding national rates, in particular the rates reported
by male respondents.
Cannabis
Reports of use of an illegal drug mainly related to cannabis,
twenty seven per cent had ever taken cannabis, 8% had done 
so in the previous year and 5% in the previous month.
Other illegal drugs
After cannabis, the next highest levels of lifetime use were
recorded for ecstasy (6%), magic mushrooms and cocaine
powder (5%). Similar levels of lifetime use were recorded for
amphetamines, LSD and poppers (each 4%). Less than one
percent of respondents surveyed reported use of heroin and crack.
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In the past year, a similar level of cocaine powder and ecstasy
use (each 2%) were reported. In the month prior to the survey,
cocaine powder (1%) was the most commonly reported drug
used, after cannabis, by those surveyed.
Levels of cocaine, ecstasy and solvent use were notably higher
than the corresponding national rates, particularly the rates
reported by male and young adult respondents.
Sedatives, tranquillisers and anti-depressants
Seventeen per cent of respondents reported ever using sedatives,
tranquillisers and anti-depressants, 9% had done so in the
previous year and 6% in the previous month. By and large, rates
were higher than the corresponding national rates, particularly the
lifetime prevalence rates reported by females and older adults.
Alcohol
Ninety four per cent of the NAHB residents surveyed reported
that they had ever taken an alcoholic drink, 89% had done so 
in the previous year and 81% in the previous month. Rates 
were higher among males and young adults and all rates 
were higher than the corresponding national rates.
Tobacco
Sixty two per cent of respondents reported ever smoking tobacco,
43% had done so in the previous year and 38% in the previous
month. Rates were somewhat higher than the national rates. 
Rates of current use were slightly higher for women (39%) 
than for men (38%).
South Eastern Health Board (SEHB)
(see Table 13)
Illegal drug use
Eighteen per cent of respondents reported they had ever taken
an illegal drug, 7% had done so in the previous year and 3% 
in the previous month. These rates were broadly similar to the
national rates.
Cannabis use accounted for most illegal drug use – 17%
reported ever taking cannabis, 6% had done so in the previous
year and 2% in the previous month.
Apart from cannabis, highest lifetime levels of use were 
recorded for magic mushrooms (6%); LSD (5%); amphetamines
and ecstasy (4%); poppers (3%); and cocaine powder (2%).
Minimal lifetime rates of crack (0.3%) were reported. No use 
of heroin was recorded by those surveyed.
The lifetime prevalence rates recorded for magic mushrooms,
LSD, amphetamines and ecstasy were higher than average with
the rates reported by male respondents particularly high. In the 
past year, the highest levels of use were recorded for cocaine
powder (2%); ecstasy and amphetamines (each 1%); magic
mushrooms (0.8%) and poppers (0.7%).
The last year prevalence rate for amphetamines, cocaine and
ecstasy were higher than the corresponding national rates.
In the month prior to the survey, ecstasy was the most widely
reported drug used (1%) aside from cannabis. No heroin or
cocaine use was reported in the previous month by those
surveyed.
Sedatives, tranquillisers and anti-depressants
Fourteen per cent of respondents reported ever using sedatives,
tranquillisers and anti-depressants, 8% had done so in the
previous year and 5% in the previous month. Highest rates were
reported by females and older adults; all rates were higher than
the corresponding national rates.
Alcohol
Eighty nine per cent of the SEHB residents surveyed reported
that they had ever taken an alcoholic drink, 84% had done so 
in the previous year and 74% in the previous month. A slightly
higher proportion of older adults (75%) than younger adults
(73%) reported current use of alcohol; this pattern was at
variance with most other health boards.
Tobacco
Sixty one per cent of respondents reported ever smoking
tobacco, 38% had done so in the previous year and 32% in 
the previous month. Prevalence rates among younger adults
were consistently higher than the corresponding national rates.
South Western Area Health Board (SWAHB)
(see Table 14)
Illegal drug use
Almost a quarter (24%) of respondents reported ever taking an
illegal drug, 8% had done so in the previous year and 4% in the
previous month. Each of these rates was higher than the
corresponding national rate.
Reports of illegal drug use mainly related to cannabis – 23% had
ever taken cannabis, 7% had done so in the previous year and
4% in the previous month. These rates were higher than the
corresponding national figures.
Apart from cannabis, highest lifetime levels of use were recorded
for ecstasy, and magic mushrooms (each 6%); amphetamines,
cocaine powder and LSD (each 5%); poppers (3%); and
solvents (2%). Minimal levels of crack use (0.4%) were
recorded by those surveyed.
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Lifetime prevalence rates for all illegal drugs, except solvents,
were higher than the national rates, particularly amphetamines
(5%) and heroin (2%).
Aside from cannabis, cocaine powder and ecstasy (each 1%)
were the most commonly reported drugs used in the past year.
Sedatives, tranquillisers and anti-depressants
Thirteen per cent of respondents reported ever using sedatives,
tranquillisers and anti-depressants, 6% had done so in the
previous year and 4% in the previous month. Rates were 
higher among females and older adults.
Alcohol
Ninety one per cent of the residents surveyed reported that 
they had ever taken an alcoholic drink, 86% had done so in 
the previous year and 73% in the previous month. Rates were
generally in line with national figures. However, a slightly higher
proportion of older adults (75%) than younger adults (72%)
reported current use of alcohol; this pattern was at variance with
most other health boards.
Tobacco
Sixty four per cent of respondents reported ever smoking
tobacco, 44% had done so in the previous year and 39% in 
the previous month. Rates were higher than the corresponding
national figures.
Southern Health Board (SHB)
(see Table 15)
Illegal drug use
Twelve per cent of respondents reported they had ever taken 
an illegal drug, 5% had done so in the previous year and 2% 
in the previous month. Illegal drug use in this health board area
primarily related to the use of cannabis for which similar rates
were reported.
Apart from cannabis, highest lifetime levels of use were recorded
for magic mushrooms and ecstasy (each 3%); cocaine powder
and amphetamines (each 2%); LSD, poppers and solvents 
(each 1%). No heroin or crack use was recorded by those
surveyed.
In the past year, cocaine powder and ecstasy (each 1%) were
the main drugs used aside from cannabis.
Overall, prevalence rates were lower than the corresponding
national rates.
Sedatives, tranquillisers and anti-depressants
Ten per cent of respondents reported ever using sedatives,
tranquillisers and anti-depressants, 4% had done so in the
previous year and 3% in the previous month.
Alcohol
Ninety one per cent of the SHB residents surveyed reported that
they had ever taken an alcoholic drink, 85% had done so in the
previous year and 75% in the previous month. These rates were
just above the corresponding national figures.
Tobacco
Fifty five per cent of respondents reported ever smoking tobacco,
35% had done so in the previous year and 31% in the previous
month. The prevalence rate for current tobacco use was higher
among females (35%) than males (28%), a pattern which was
at variance to that reported at national level.
Western Health Board (WHB)
(see Table 16)
Illegal drug use
Twelve per cent of respondents reported ever having taken 
an illegal drug, 3% had done so in the previous year and 
2% in the previous month. These rates were lower than the
corresponding national rates. Most reports of illegal drug use
related to cannabis use.
Apart from cannabis, highest lifetime levels of use were recorded
for magic mushrooms and ecstasy (each 2%); cocaine powder,
LSD, amphetamines and poppers (each 1%). No heroin use 
was reported and minimal levels of solvents (0.4) and crack 
use (0.1%) were recorded by those surveyed.
Sedatives, tranquillisers and anti-depressants
Ten per cent of respondents reported ever using sedatives,
tranquillisers and anti-depressants, 6% had done so in the 
previous year and 4% in the previous month.
Alcohol
Eighty eight per cent of respondents reported that they had 
ever taken an alcoholic drink, 77% had done so in the previous
year and 67% in the previous month. Figures for lifetime, 
recent and current use were all lower than national figures.
Tobacco
Sixty one per cent of respondents reported ever smoking
tobacco, 36% had done so in the previous year and 32% 
in the previous month. Rates among young adults were lower 
than the corresponding national figures. The prevalence rate 
for current tobacco use was higher among females (33%) 
than males (31%), a pattern which was at variance to that
reported at national level.
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